Nature Reviews Drug Discovery 16, 545–564 (2017)
The compounds APD371,LY2828360, S-777469 and KHK6188 were incorrectly referred to as inhibitors of the cannabinoid receptors CB1 and CB2 in Table 1, when they are cannabinoid receptor agonists. In addition, KHK6188 is not currently in a Phase 2 clinical trial for neuropathic pain as stated in Table 1 and development of this agent has been discontinued. The error has been corrected in the html and pdf versions online.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.87
Rights and permissions
About this article
Cite this article
Yekkirala, A., Roberson, D., Bean, B. et al. Erratum: Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov 16, 810 (2017). https://doi.org/10.1038/nrd.2017.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.202
This article is cited by
-
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
Drugs - Real World Outcomes (2021)
-
Novel Analgesics with Peripheral Targets
Neurotherapeutics (2020)
-
Recurrent antinociception induced by intrathecal or peripheral oxytocin in a neuropathic pain rat model
Experimental Brain Research (2019)
